Is cosyntropin the same as ACTH?

Not exactly. Cosyntropin is a synthetic 24-amino acid peptide that replicates ACTH's biological activity. Natural ACTH is 39 amino acids; cosyntropin is shorter but binds the same receptor and triggers the same cortisol response. For diagnostic purposes, they're functionally equivalent, but cosyntropin is easier to manufacture and standardize.

What does an abnormal cosyntropin test result mean?

A blunted cortisol response (cortisol <18 μg/dL at 30–60 minutes) suggests the adrenal glands aren't responding normally. This could indicate primary adrenal insufficiency (adrenal gland failure), secondary adrenal insufficiency (pituitary/hypothalamic dysfunction), or adrenal suppression from medications. Further testing and clinical evaluation are needed to determine the cause.

Is cosyntropin safe for repeated testing?

Yes. Cosyntropin is well-tolerated and can be used for repeated diagnostic testing if clinically indicated. The dose used diagnostically (1–250 mcg) is far below doses that would trigger systemic effects. Adverse events are rare and mild. Always inform your healthcare provider of prior reactions to ACTH or peptides.

Why isn't cosyntropin approved in Europe or Canada?

Regulatory approval varies by region and depends on application timelines, regional data requirements, and manufacturer registration efforts. Lack of EMA or Health Canada approval doesn't reflect safety concerns—it's primarily administrative. European and Canadian practitioners use alternative diagnostic methods or work within research frameworks.

Can cosyntropin be used as a treatment, not just a diagnostic?

Cosyntropin's clinical role is diagnostic, not therapeutic. It's used to test adrenal function, not to treat adrenal insufficiency. Patients with adrenal insufficiency are treated with glucocorticoid and/or mineralocorticoid replacement therapy, not with cosyntropin stimulation.

Cosyntropin Complete Guide: Mechanism, Evidence & Uses

Q: Is cosyntropin safe for repeated testing?

Yes. Cosyntropin is well-tolerated and can be used for repeated diagnostic testing if clinically indicated. The dose used diagnostically (1–250 mcg) is far below doses that would trigger systemic effects. Adverse events are rare and mild. Always inform your healthcare provider of prior reactions to ACTH or peptides.

Q: Why isn't cosyntropin approved in Europe or Canada?

Regulatory approval varies by region and depends on application timelines, regional data requirements, and manufacturer registration efforts. Lack of EMA or Health Canada approval doesn't reflect safety concerns—it's primarily administrative. European and Canadian practitioners use alternative diagnostic methods or work within research frameworks.

Q: Can cosyntropin be used as a treatment, not just a diagnostic?

Cosyntropin's clinical role is diagnostic, not therapeutic. It's used to test adrenal function, not to treat adrenal insufficiency. Patients with adrenal insufficiency are treated with glucocorticoid and/or mineralocorticoid replacement therapy, not with cosyntropin stimulation.

Cosyntropin is a synthetic peptide that mimics adrenocorticotropic hormone (ACTH), a naturally occurring hormone that stimulates cortisol production. It's FDA-approved for diagnostic testing of adrenal function—specifically, to evaluate whether the adrenal glands respond properly to hormonal signaling. Unlike many research compounds, cosyntropin has decades of clinical use behind it, with 38 registered clinical trials investigating its applications. It's primarily used by doctors as a diagnostic tool rather than a treatment, making it a cornerstone of endocrinology testing. This guide covers the science, evidence, regulatory status, and clinical applications you need to understand this compound.

What Is Cosyntropin? The Basics

Cosyntropin is a synthetic 24-amino acid peptide manufactured to replicate the biological activity of adrenocorticotropic hormone (ACTH), a hormone produced naturally by the pituitary gland. ACTH's primary job is straightforward: it tells the adrenal glands to produce and release cortisol, a glucocorticoid hormone critical for metabolism, stress response, and immune function.

Because cosyntropin behaves identically to natural ACTH in the body, it can be used diagnostically to assess adrenal responsiveness. If you inject cosyntropin intravenously or intramuscularly, a healthy adrenal system will respond by releasing cortisol into the bloodstream. By measuring that cortisol response, doctors can determine whether the adrenal glands are functioning normally.

The compound is marketed under the brand name Cortrosyn (in the US) and is listed as an FDA-approved medication, making it one of the few peptide therapeutics with full regulatory clearance for clinical use.

How Cosyntropin Works: The Mechanism

Cosyntropin's mechanism is elegant in its simplicity. The compound binds to ACTH receptors (melanocortin-2 receptors or MC2-R) located on the surface of adrenocortical cells in the adrenal cortex. This receptor binding initiates an intracellular signaling cascade that stimulates three key processes:

Cortisol synthesis and release: The primary response. Activated adrenocortical cells increase the enzymatic conversion of cholesterol to cortisol and release it into circulation.
Gene expression changes: Cosyntropin upregulates genes involved in steroid hormone synthesis, preparing the adrenal gland for sustained response.
Cellular proliferation: Chronic ACTH exposure triggers growth of adrenocortical cells, though this is primarily relevant in long-term use scenarios, not diagnostic testing.

The time course matters clinically. Peak cortisol levels typically occur 30–60 minutes after cosyntropin administration, which is why the cosyntropin stimulation test involves administering the compound and then measuring cortisol at defined intervals (often baseline, 30 min, and 60 min).

Because cosyntropin is synthetic and much shorter-acting than endogenous ACTH (which is continuously released), it provides a controlled, reproducible stimulus—ideal for diagnostic testing.

Clinical Evidence: What 38 Trials Tell Us

Cosyntropin has one of the most robust evidence bases in diagnostic endocrinology. The 38 registered clinical trials span decades and cover a spectrum of clinical questions:

Adrenal Insufficiency Diagnosis

The gold standard application. Multiple studies confirm that a normal cortisol response to cosyntropin (typically >18 μg/dL at 30 or 60 minutes) effectively rules out primary adrenal insufficiency. Conversely, a blunted response suggests adrenal dysfunction.

Secondary Adrenal Insufficiency

Cosyntropin is particularly useful for diagnosing secondary adrenal insufficiency (caused by pituitary or hypothalamic pathology). Research demonstrates that a normal response to cosyntropin can exclude pituitary ACTH deficiency, while an abnormal response suggests central dysfunction.

Critical Illness and Sepsis

Several trials investigated cosyntropin's diagnostic role in critically ill patients. The low-dose cosyntropin test (250 mcg IV) has been studied extensively as a screening tool for relative adrenal insufficiency in septic shock, though clinical practice remains variable.

Congenital Adrenal Hyperplasia (CAH)

Cosyntropin stimulation testing is standard for diagnosing and monitoring CAH, a genetic disorder affecting cortisol synthesis. Studies confirm its utility in identifying enzyme defects based on precursor hormone accumulation during stimulation.

Drug-Induced Adrenal Suppression

Cosyntropin testing is used to assess whether medications (particularly glucocorticoids or certain immunosuppressants) have suppressed the adrenal axis. Normal cosyntropin response suggests the axis is intact.

These trials, collectively, have established cosyntropin as the diagnostic standard for adrenal function testing—a rare achievement for a peptide compound.

Regulatory Status: FDA Approval & Global Authorization

Cosyntropin holds FDA approval in the United States, classified as a prescription medication for diagnostic purposes. This approval is based on decades of clinical data demonstrating safety and diagnostic utility.

US Status: FDA-approved. The compound is available by prescription only.

EU Status: Not authorized by the European Medicines Agency (EMA). While ACTH-based diagnostics are used in Europe, cosyntropin specifically lacks EMA marketing authorization, though ACTH itself and some alternatives may be available under different regulatory pathways.

Canada Status: Not approved by Health Canada. Canadian practitioners may have access to alternative diagnostic modalities or may work within research frameworks.

This regulatory fragmentation reflects differences in approval timelines and regulatory standards across regions but doesn't reflect differences in safety or efficacy—it's primarily administrative.

Safety Profile: What the Data Shows

Cosyntropin is remarkably well-tolerated, which is one reason it's become the diagnostic standard. Adverse events are uncommon and typically mild.

Common Reactions

Mild, transient reactions occur in a small percentage of patients:

Flushing or facial erythema
Mild headache
Dizziness
Nausea (rare)

These usually resolve within minutes and are not medically significant.

Serious Adverse Events

Serious reactions are exceptionally rare. Anaphylaxis has been reported in isolated cases, primarily in patients with a prior history of allergic reactions to ACTH or other peptides, but the absolute incidence is extremely low.

Contraindications and Caution

Allergy to cosyntropin or ACTH: Absolute contraindication.
Systemic infections: Some protocols recommend caution, as ACTH can exacerbate certain infections, though this is debated clinically.
Pregnancy and lactation: Limited safety data; use only if diagnostic benefit justifies potential risk (typically reserved for urgent diagnostic scenarios).

Because cosyntropin is used diagnostically in a single dose (or occasionally a low-dose repeated test), chronic toxicity concerns that apply to long-term peptide use don't apply here.

The Cosyntropin Stimulation Test: How It Works in Practice

Understanding the actual diagnostic test helps contextualize cosyntropin's clinical role:

Standard Protocol (High-Dose Test):

Baseline cortisol sample drawn.
250 mcg cosyntropin administered IV or IM.
Cortisol measured at 30 and 60 minutes.
Normal response: cortisol rises to >18–20 μg/dL (threshold varies slightly by lab).

Low-Dose Test:

Baseline cortisol sample.
1 mcg cosyntropin administered IV (sometimes called the "1 mcg test").
Cortisol measured at 30 minutes.
Interpretation similar to high-dose test; some argue it's more sensitive for detecting mild adrenal dysfunction.

The test is quick, safe, and reproducible—hallmarks of a good diagnostic tool.

Cosyntropin vs. Alternative Diagnostics

While cosyntropin is standard, practitioners sometimes consider alternatives:

Insulin tolerance test (ITT): Gold standard for assessing the entire hypothalamic-pituitary-adrenal (HPA) axis, but more complex and carries hypoglycemia risk.
Metyrapone test: Assesses pituitary function by blocking cortisol synthesis; requires careful monitoring.
CRH (corticotropin-releasing hormone) stimulation test: Evaluates pituitary responsiveness; less commonly used now.

Cosyntropin remains preferred for adrenal insufficiency screening because it's safe, direct, and widely available.

Key Takeaways

Cosyntropin is a synthetic ACTH analog with FDA approval and 38 clinical trials supporting its use as a diagnostic tool for assessing adrenal function. Its safety profile is excellent, its mechanism is well-understood, and its clinical utility is well-established. It's not a treatment—it's a diagnostic agent that helps doctors answer a specific question: "Are the adrenal glands responding normally to hormonal signaling?" For that purpose, it's become the standard of care in endocrinology.

If you're interested in other peptide diagnostics or the broader landscape of ACTH-related compounds, PeptideTrace has detailed profiles on related substances and the HPA axis regulatory system.

Cosyntropin: The Complete Guide to This FDA-Approved Diagnostic Peptide